Browse

Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage (WHO label)	Target Gene	Primer Name	Primer Sequence	Primer Length	Primer GC Content (%)	Start Position	End Position	Primer Direction	ΔG (cal)	Primer first used
XAY.2.2	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BF.3	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BF.3	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BF.7.10	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BF.7.10	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
CM.8.1.4	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
CM.8.1.4	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BF.7.5.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BF.7.5.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XBF.3	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
XBF.3	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BZ.2	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BZ.2	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BQ.1.10.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BQ.1.10.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BF.7.24	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BF.7.24	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.5.10	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.5.10	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.2.44	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.2.44	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.2.6	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.2.6	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
EA.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
EA.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.2.22	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.2.22	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
DH.1	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
DH.1	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
XG	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
XG	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BF.6	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BF.6	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.5.3.2	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.5.3.2	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.5.2.7	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.5.2.7	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BE.2	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BE.2	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BQ.1.1.9	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BQ.1.1.9	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BF.11.3	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BF.11.3	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.4.5	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.4.5	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.2.54	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BA.2.54	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BF.18	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
BF.18	N	SC2	CCTTGTGTGGTCTGCATGAGTTTAG	25	48	29554	29530	R	-26482.3	US
BA.2.52	N	SC2	CTGCAGATTTGGATGATTTCTCC	23	43.48	29463	29485	F	-23117.2	US
Lineage (WHO label)	Target Gene	Primer Name	Primer Sequence	Primer Length	Primer GC Content (%)	Start Position	End Position	Primer Direction	ΔG (cal)	Primer first used